Pradeep Prasad, MD
Ophthalmology · Los Angeles, CANPI 1639348204
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $53,355 of the $77,040 with a category attached, or 69.3%. Regeneron Healthcare Solutions, Inc. accounts for 65.0% of it on its own, with 15 other manufacturers making up the rest. 2025 is the largest year on record at $29,468, 4.7 times the $6,226 reported in 2019. Among ophthalmology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 158 payments — averaging $487.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$50K
- Dutch Ophthalmic, USA$8K
- AbbVie$6K
- Novartis$4K
- Alimera Sciences, Inc.$3K
- Genentech, Inc.$2K
- plus $3K from 10 others
Across 95 payments — averaging $8674.93 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Roche TCRC, Inc.$415K
- Novartis$239K
- Regeneron$99K
- Janssen Research & Development, LLC$71K
What the payments were for
- Consulting fees$11,20015%
- Speaking & faculty fees$53,35569%
- Travel & lodging$3,0004%
- Food & beverage$9,48512%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 34 | $50,088 |
| Dutch Ophthalmic, USA | 14 | $8,494 |
| AbbVie(2 entities) | 51 | $5,988 |
| Novartis | 15 | $3,893 |
| Alimera Sciences, Inc. | 13 | $3,429 |
| Genentech, Inc. | 1 | $2,000 |
| Alcon | 9 | $1,075 |
| Astellas Pharma US Inc | 7 | $599 |
| Apellis Pharmaceuticals, Inc. | 5 | $525 |
| Genentech USA, Inc. | 2 | $277 |
| Carl Zeiss Meditec USA, Inc. | 2 | $168 |
| Bausch & Lomb Americas Inc. | 1 | $128 |
| Aquestive Therapeutics, Inc. | 1 | $128 |
| Sunovion Pharmaceuticals Inc. | 1 | $117 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $114 |
| Ultragenyx Pharmaceutical Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EYLEA HD$49,602
- EVA, combined machine$4,865
- OZURDEX$4,860
- EVA Ophthalmic Surgical System$3,629
- Iluvien$3,150
- BEOVU$2,620
- TISSUEBLUE$2,615
- Lucentis$2,000
- VABYSMO$277
- Syfovre$261
- Izervay$257
- EYLEA$250
- QUATERA 700$153
- IOLMaster 700$153
- AcrySof$141
- STELLARIS$128
- SYMPAZAN$128
- BUPARLISIB$122
- APTIOM$117
- PanOptix$115
How this compares
$77,040 in reported general payments places this provider in the 95th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 25 | $21,341 |
| Bromfenac Sodium | 22 | $3,121 |
| Prednisolone Acetate | 84 | $2,932 |
| Difluprednate | 20 | $2,899 |
| Ketorolac Tromethamine | 64 | $1,418 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 48 | $733 |
| MoxifloxacinMoxifloxacin Hcl | 18 | $439 |
| Atropine Sulfate | 14 | $368 |
| Brimonidine Tartrate | 40 | $330 |
| Timolol Maleate | 31 | $105 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis | $5,988 | $21,34125 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,513 ophthalmology providers in California.
Other ophthalmology in Los Angeles
- Andrew MoshfeghiLos Angeles$895K
- Barry SeibelLos Angeles$835K
- Nicole FramLos Angeles$551K
- Neda ShamieLos Angeles$547K
- David BoyerLos Angeles$406K
- David HamiltonLos Angeles$359K
- Arjan HuraLos Angeles$306K
- Firas RahhalLos Angeles$264K
- Kouros NourimahdaviLos Angeles$258K
- Daniel RootmanLos Angeles$247K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.